APN sets FY 2027 targets: ZAR 9bn+ EBITDA and 50%+ NHEPS growth
Aspen Pharmacare says it delivered strong EBITDA and NHEPS growth despite flat revenue. It targets FY 2027 EBITDA over ZAR 9 billion, 50%+ NHEPS growth, and robust free cash flow, prioritizing share buybacks.